Parameters | Kochujang group (n=30) | Placebo group (n=30) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
0wk | 12wk | Change* | 0wk | 12wk | Change* | P value1 | P value2 | P value3 | P value41 | |
Total cholesterol(mg/dL) | 193.4±5.1 | 189.8±5.9 | -3.6±3.9 | 196.4±6.3 | 197.9±5.1 | 1.5±4.2 | 0.378 | 0.047 | 0.740 | 0.367 |
Triglycerides(mg/dL) | 112.5±9.1 | 94.6±5.8 † | -17.9±8.5 | 125.6±12.7 | 139.1±13.8 | 13.5±12.9 | 0.049 | 0.412 | 0.026 | 0.042 |
HDL (mg/dL) | 52.3±1.9 | 51.2±1.9 | -1.07±1.5 | 52.3±2.2 | 50.9±1.8 | -1.32±1.7 | 0.912 | 0.100 | 0.923 | 0.670 |
LDL (mg/dL)) | 124.9±4.7 | 122.3±5.2 | -0.25±0.14 | 125.9±6.1 | 123.6±5.3 | -0.15±0.14 | 0.630 | 0.188 | 0.874 | 0.960 |
Free fatty acid (μEq/L) | 631.8±43.2 | 604.7±37.4 | -27.1±53.9 | 542.2±34.7 | 631.9±43.0 | 89.8±44.0 | 0.098 | 0.658 | 0.669 | 0.170 |
ApoA1 (g/dL) | 1.44±0.03 | 1.26±0.03 † | -0.18±0.03 | 1.45±0.04 | 1.31±0.03 † | -0.14±0.03 | 0.284 | 0.002 | 0.729 | 0.216 |
ApoB(g/dL) | 0.87±0.03 | 0.70±0.03 † | -0.17±0.02 | 0.88±0.04 | 0.76±0.04 † | -0.12±0.02 | 0.049 | 0.001 | 0.540 | 0.025 |
Atherosclerosis Indices | ||||||||||
TC/HDL | 3.8±0.1 | 3.4±0.2 | -0.42±0.2 | 3.9±0.2 | 3.8±0.2 | -0.10±0.2 | 0.303 | 0.935 | 0.460 | 0.357 |
LDL/HDL | 2.4±0.1 | 2.2±0.1 | -0.25±0.1 | 2.5±0.2 | 2.3±0.2 | -0.15±0.1 | 0.630 | 0.976 | 0.671 | 0.752 |
(TC-HDL)/HDL | 2.8±0.1 | 2.5±0.2 | -0.32±0.2 | 2.9±0.2 | 2.8±0.2 | -0.04±0.03 | 0.253 | 0.975 | 0.454 | 0.297 |
ApoB/ApoA1 | 0.61±0.02 | 0.56±0.03 † | -0.05±0.01 | 0.61±0.03 | 0.60±0.03 | -0.01±0.02 | 0.296 | 0.075 | 0.240 | 0.593 |